Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002925 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
A Phase 1 study of Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 410
- Enrollment target
- 20
- Study locations
NCT00002925 is a Phase 1 study of Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 410 participants, below the 485-participant average among 233 other Leukemia trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00002925, a Phase 1 study of Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 410 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers may become resistant to chemotherapy drugs. Combining PSC 833 with chemotherapy may reduce resistance to the drugs and allow the cancer cells to be killed. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus PSC 833 followed by additional chemotherapy or peripheral stem cell transplantation and interleukin-2 in treating patients with untreated acute myelogenous leukemia.
Conditions Studied
Interventions
- DRUG Etoposide
- DRUG Daunorubicin
- BIOLOGICAL Aldesleukin
- DRUG ara-C
- DRUG PSC-833
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- CCOP - North Shore University Hospital - Manhasset
- North Shore University Hospital - Manhasset
- Memorial Sloan-Kettering Cancer Center - New York
California
- University of California San Diego Cancer Center - La Jolla
- UCSF Cancer Center and Cancer Research Institute - San Francisco
Illinois
- University of Illinois at Chicago Health Sciences Center - Chicago
- University of Chicago Cancer Research Center - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
- University of Massachusetts Memorial Medical Center - Worcester
Missouri
- Ellis Fischel Cancer Center - Columbia - Columbia
- Barnes-Jewish Hospital - St Louis
Delaware
- CCOP - Christiana Care Health Services - Wilmington
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Florida
- CCOP - Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 1997-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002925
The ClinicalTrials.gov registry entry for NCT00002925 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 485-participant average among 233 other Leukemia trials with a reported enrollment target (15% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Etoposide is the first listed.
NCT00002925 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00002925 about?
NCT00002925 is a clinical study titled "Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers may become resistant to chemotherapy drugs. Combining PSC 833 with chemotherapy may reduce resistance to the drugs and allow the cancer cells to be killed. Interleuki...
What is the current status of trial NCT00002925?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 410 participants. The study started on 1997-02. Estimated completion is 2010-06.
What conditions does trial NCT00002925 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00002925?
The interventions under investigation include: Etoposide (DRUG), Daunorubicin (DRUG), Aldesleukin (BIOLOGICAL), ara-C (DRUG), PSC-833 (DRUG).
Who is sponsoring clinical trial NCT00002925?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002925 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.